On future's doorstep: RNA interference and the pharmacopeia of tomorrow

Journal of Clinical Investigation

Volumn 117, Issue 12, 2007, Pages 3612-3614

  Gewirtz, Alan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; MESSENGER RNA; MICRORNA; NUCLEIC ACID; RIBONUCLEASE H; SMALL INTERFERING RNA;

ANTISENSE THERAPY; COMPLEX FORMATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC CODE; HUMAN; MEDICAL LITERATURE; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RNA BINDING; RNA INTERFERENCE;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PHARMACOPOEIAS AS TOPIC; RNA INTERFERENCE; RNA STABILITY; RNA, SMALL INTERFERING;

EID: 36849084647     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34274     Document Type: Review

References (63)

1. Terui, Y., et al. 1995. Expression of differentiation-related phenotypes and apoptosis are independently regulated during myeloid cell differentiation. J. Biochem. (Tokyo) 117:77-84.
2. Sawyers, C.L. 2001. Research on resistance to cancer drug Gleevec. Science. 294:1834.
3. Friedberg, J.W. 2005. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am. Soc. Hematol. Educ. Program. 2005:329-334.
4. Casey, B.P., and Glazer, P.M. 2001. Gene targeting via triple-helix formation. Prog. Nucleic Acid Res. Mol. Biol. 67:163-192.
5. Urbach, A.R., and Dervan, P.B. 2001. Toward rules for 1:1 polyamide:DNA recognition. Proc. Natl. Acad. Sci. U. S. A. 98:4343-4348.
6. Durai, S., et al. 2005. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res. 33:5978-5990.
7. Gewirtz, A.M., Sokol, D.L., and Ratajczak, M.Z. 1998. Nucleic acid therapeutics: state of the art and future prospects. Blood. 92:712-736.
8. Opalinska, J.B., and Gewirtz, A.M. 2002. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1:503-514.
9. Dervan, P.B., and Burli, R.W. 1999. Sequence-specific DNA recognition by polyamides. Curr. Opin. Chem. Biol. 3:688-693.
10. Opalinska, J.B., and Gewirtz, A.M. 2003. Therapeutic potential of antisense nucleic acid molecules. Sci. STKE. 2003:pe47.
11. Rossi, J.J. 2006. RNAi therapeutics: SNALPing siRNAs in vivo. Gene Ther. 13:583-584.
12. Kole, R., and Sazani, P. 2001. Antisense effects in the cell nucleus: modification of splicing. Curr. Opin. Mol. Ther. 3:229-234.
13. Dominski, Z., and Kole, R. 1994. Identification and characterization by antisense oligonucleotides of exon and intron sequences required for splicing. Mol. Cell. Biol. 14:7445-7454.
14. Summerton, J., et al. 1997. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. 7:63-70.
15. Iversen, P.L. 2001. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. 3:235-238.
16. Zamaratski, E., Pradeepkumar, P.I., and Chattopadhyaya, J. 2001. A critical survey of the structurefunction of the antisense oligo/RNA heteroduplex as substrate for RNase H. J. Biochem. Biophys. Methods. 48:189-208.
17. Crooke, S.T. 1998. Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev. 8:133-134.
18. Castanotto, D., Scherr, M., and Rossi, J.J. 2000. Intracellular expression and function of antisense catalytic RNAs. Methods Enzymol. 313:401-420.
19. Rossi, J.J. 1999. Ribozymes in the nucleolus. Science. 285:1685.
20. Santoro, S.W., and Joyce, G.F. 1997. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U. S. A. 94:4262-4266.
21. Wu, Y., et al. 1999. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum. Gene Ther. 10:2847-2857.
22. Hannon, G.J. 2002. RNA interference. Nature. 418:244-251.
23. Martinez, J., et al. 2002. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 110:563-574.
24. Hexner, E.O., and Gewirtz, A.M. 2005. RNA interference for treating haematological malignancies. Expert Opin. Biol. Ther. 5:1585-1592.
25. Grunweller, A., and Hartmann, R.K. 2005. RNA interference as a gene-specific approach for molecular medicine. Curr. Med. Chem. 12:3143-3161.
26. Fire, A.Z. 2007. Gene silencing by double-stranded RNA (Nobel lecture). Angew Chem. Int. Ed. Engl. 46:6966-6984.
27. Couzin, J. 2006. Nobel Prize in Physiology or Medicine. Method to silence genes earns loud praise. Science. 314:34.
28. Bots, M., Maughan, S., and Nieuwland, J. 2006. RNAi Nobel ignores vital groundwork on plants. Nature. 443:906.
29. Hutvagner, G., et al. 2001. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 293:834-838.
30. Ketting, R.F., et al. 2001. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15:2654-2659.
31. Nicholson, R.H., and Nicholson, A.W. 2002. Molecular characterization of a mouse cDNA encoding Dicer, a ribonuclease III ortholog involved in RNA interference. Mamm. Genome. 13:67-73.
32. Filipowicz, W. 2005. RNAi: the nuts and bolts of the RISC machine. Cell. 122:17-20.
33. Hammond, S.M., Caudy, A.A., and Hannon, G.J. 2001. Post-transcriptional gene silencing by double-stranded RNA. Nat. Rev. Genet. 2:110-119.
34. Parker, J.S., Roe, S.M., and Barford, D. 2004. Crystal structure of a PIWI protein suggests mechanisms for siRNA recognition and slicer activity. EMBO J. 23:4727-4737.
35. Rivas, F.V., et al. 2005. Purified Argonaute2 and an siRNA form recombinant human RISC. Nat. Struct. Mol. Biol. 12:340-349.
36. Han, J., et al. 2004. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18:3016-3027.
37. Carmell, M.A., and Hannon, G.J. 2004. RNase III enzymes and the initiation of gene silencing. Nat. Struct. Mol. Biol. 11:214-218.
38. Pasquinelli, A.E. 2002. MicroRNAs: deviants no longer. Trends Genet. 18:171-173.
39. Chen, C.Z., et al. 2004. MicroRNAs modulate hematopoietic lineage differentiation. Science. 303:83-86.
40. Calin, G.A., and Croce, C.M. 2006. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin. Oncol. 33:167-173.
41. Kim, Y.K., and Kim, V.N. 2007. Processing of intronic microRNAs. EMBO J. 26:775-783.
42. Cejka, D., Losert, D., and Wacheck, V. 2006. Short interfering RNA (siRNA): tool or therapeutic? Clin. Sci. (Lond.) 110:47-58.
43. Liao, H., and Wang, J.H. 2005. Biomembrane-permeable and Ribonuclease-resistant siRNA with enhanced activity. Oligonucleotides. 15:196-205.
44. Brown, K.M., Chu, C.Y., and Rana, T.M. 2005. Target accessibility dictates the potency of human RISC. Nat. Struct. Mol. Biol. 12:469-470.
45. Patzel, V., et al. 2005. Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency. Nat. Biotechnol. 23:1440-1444.
46. Spagnou, S., Miller, A.D., and Keller, M. 2004. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry. 43:13348-13356.
47. Sioud, M. 2005. siRNA delivery in vivo. Methods Mol. Biol. 309:237-249.
48. Lassus, P., Rodriguez, J., and Lazebnik, Y. 2002. Confirming specificity of RNAi in mammalian cells. Sci. STKE. 2002:PL13.
49. Hornung, V., et al. 2005. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11:263-270.
50. Zhang, Z., et al. 2006. siRNA binding proteins of microglial cells: PKR is an unanticipated ligand. J. Cell. Biochem. 97:1217-1229.
51. Zhang, Y.C., et al. 2005. Antisense inhibition: oligonucleotides, ribozymes, and siRNAs. Methods Mol. Med. 106:11-34.
52. Bitko, V., et al. 2005. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11:50-55.
53. Corey, D.R. 2007. Chemical modification: the key to clinical application of RNA interference? J. Clin. Invest. 117:3615-3622.
54. Beltinger, C., et al. 1995. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95:1814-1823.
55. Hunter, C.P., et al. 2006. Systemic RNAi in Caenorhabditis elegans. Cold Spring Harb. Symp. Quant. Biol. 71:95-100.
56. Wolfrum, C., et al. 2007. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25:1149-1157.
57. Akhtar, S., and Benter, I.F. 2007. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 117:3623-3632.
58. Grimm, D., and Kay, M.A. 2007. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J. Clin. Invest. 117:3633-3641.
59. Fattal, E., and Bochot, A. 2006. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv. Drug Deliv. Rev. 58:1203-1223.
60. Hadj-Slimane, R., et al. 2007. Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis. Biochimie. 89:1234-1244.
61. de Fougerolles, A., et al. 2007. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6:443-453.
62. Frantz, S. 2006. Safety concerns raised over RNA interference. Nat. Rev. Drug Discov. 5:528-529.
63. Grimm, D., et al. 2006. Fatality in mice due to over-saturation of cellular microRNA/short hairpin RNA pathways. Nature. 441:537-541.